DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for hypophosphatemia — screening already-approved drugs against its 5-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleHypophosphatemia maps to a 5-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for hypophosphatemia is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
vitamin D receptor (VDR) — VDR is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 1~{s},3~{z}drag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8IQN · 1.639 Å · ligand (1~{S},3~{Z})-3-[(2~{E})-2-[(1~{R},3~{a}~{S},7~{a}~{R})-1-[(2~{R})-5,5-bis(fluoranyl)-6-methyl-6-oxidanyl-heptan-2-yl]-7~{a}-methyl-2,3,3~{a},5,6,7-hexahydro-1~{H}-inden-4-ylidene]ethylidene]-4-methylidene-cyclohexan-1-ol (SRF). Experimental structure, not a prediction.
What the evidence adds up to
Severe hypophosphatemia, defined as serum phosphate below 1 mg%, is associated with significant morbidity in hospitalised patients and can affect every organ system. Specialised nutrition support is an important factor that contributes to the development of this metabolic disorder, and patients receiving such support exhibit increased phosphorus demands requiring aggressive replacement therapy. Current treatment regimens for hypophosphatemia are empiric and often fail to normalise serum phosphorus concentrations.
A 2015 case report describes a 65-year-old female who presented with abdominal pain, watery stools and vomiting for three days, then developed abdominal distension and breathlessness, and was finally diagnosed with hypophosphatemia. The report states that correction of acute hypophosphatemia leaves no long-term complications, but failure to recognise and treat an acute situation can be fatal. The authors emphasise that hypophosphatemia is often underestimated in critically ill patients.
Phosphate deficiency can result from decreases in phosphate intake or absorption, increased loss from renal and nonrenal pathways, and transcellular phosphate shifts. Optimum therapy is directed at recognising patients at greatest risk, correcting the underlying abnormality, and supplementing phosphate intake. Intravenous phosphate therapy is indicated for severe hypophosphatemia with close monitoring of serum phosphate, calcium, potassium, and magnesium levels.
No controlled trial data are available to define optimal dosing, duration, or monitoring schedules for phosphate replacement in hypophosphatemia. What is still missing is prospective, randomised evidence comparing different replacement strategies, particularly in the subset of patients receiving nutrition support, and validated protocols that account for individual variation in phosphate demands.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Nutrition in Clinical Practice · 1994 · 24 citations
Observations of Hypophosphatemia and Its Management in Nutrition Support
AbstractSevere hypophosphatemia is associated with significant morbidity in hospitalized patients. Specialized nutrition support is an important factor that contributes to the development of this metabolic disorder. Current treatment regimens for hypophosphatemia are empiric and often fail to normalize serum phosphorus concentrations in these patients. Patients who develop hypophosphatemia during the administration of specialized nutrition support exhibit increased phosphorus demands and require aggressive replacement therapy.
Journal of Clinical Pharmacy and Therapeutics · 2015 · 6 citations
Managing hypophosphatemia in critically ill patients: a report on an under-diagnosed electrolyte anomaly
AbstractWHAT IS KNOWN AND OBJECTIVE: Correction of acute hypophosphatemia leaves no long-term complications, but failure to recognize and treat an acute situation can be fatal. CASE SUMMARY: A 65-year-old female presented to the Emergency department with complaints of abdominal pain, multiple episodes of watery stools and vomiting for 3 days. On the 3rd day, she developed abdominal distension and breathlessness and was referred to this hospital for further management and finally diagnosed with hypophosphatemia. WHAT IS NEW AND CONCLUSION: As hypophosphatemia is often underestimated, this case report emphasizes the importance of correcting hypophosphatemia in all critically ill patients.
AbstractHypophosphatemia, defined as serum phosphate levels less than 2.5 mg%, is a relatively common disorder that can affect virtually every organ system. Phosphate deficiency can result from decreases in phosphate intake or absorption, increased loss from renal and nonrenal pathways, and transcellular phosphate shifts. Optimum therapy is directed at recognizing patients at greatest risk, correcting the underlying abnormality, and supplementing phosphate intake. Intravenous phosphate therapy is indicated for severe hypophosphatemia (serum phosphate less than 1 mg%) with close monitoring of serum phosphate, calcium, potassium, and magnesium levels. Indications for phosphate therapy and suggestions for empirical iv therapy in severe hypophosphatemia are presented.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
